T: 1.800.268.5058
F: 289.288.0020
Cellutions6.jpg
News and Events
Latest Release: Pituitary Cell Lines and Article from Dr. Denise Belsham
Monday, 25 April 2011

 

Latest Release: Pituitary Cell Lines and Article from Dr. Denise Belsham

Download the latest brochure containing information regarding the hypothalamic, hippocampal and the newly released pituitary cell lines. Also read an article from the originator of the cell lines, Denise Belsham entitled:

  • And so the little neuron said to the big neuron… Adult-derived Hypothalamic Cell Lines to Study Neuronal Regulation
 
Now Available: Embryonic Rat Hypothalamic Cell Lines
Tuesday, 16 December 2008

Using the same proprietary platform technology used to produce our embryonic mouse cell line, we have created of a series of Rat hypothalamic neurons immortalized from rat embryonic day 18 hypothalamic primary cultures. The resulting 22 phenotypically distinct cell lines have been screening for over 25 different neuropeptides, enzymatic markers and biologically active receptors. Please click here for further details.

 
CEDARLANE acquires CELLutions Biosystems Inc.
Friday, 30 November 2007

CEDARLANE announced the acquisition of CELLutions Biosystems Inc. to create a powerful combination in the Canadian biotechnology industry.

“This is a very exciting development for these two important players (in the Life Science research community),” says Dr. Tim McTiernan, Assistant Vice-President of Research and Executive Director of The Innovations Group, University of Toronto. “CEDARLANE’s acquisition of CELLutions means the development of sound and sustainable products to aid in the understanding of complex human diseases and to assist in the development of new and effective treatments.”

“CELLutions is on its way to becoming a leading distributor of cell lines and other biological tools for the research and development market,” says Cynthia Greer, President of CEDARLANE. “As an established, leading manufacturer and distributor, we can maximize CELLutions’ potential, and work together to find solutions to important health issues facing Canadians and people worldwide.”

 
Sales Breakthrough for Canadian-made Biological Research Technology
Monday, 14 February 2005

Canada's reputation as a provider of leading biological research technology has been expanded with the signing of an international distribution agreement for cell lines marketed by CELLutions Biosystems, a company founded by the University of Toronto's Innovations Foundation.

The three-year agreement, signed in early January, gives Cosmo Bio Co. Ltd. of Tokyo, Japan, exclusive distribution rights within Japan. "We expect there will be strong demand within the drug discovery field for the unique cell lines provided by CELLutions," said Masanori Harada, President of Cosmo Bio.

Paul Truscott, Vice-President - Business Development, CELLutions Biosystems, is equally optimistic about the marketability of the cell lines worldwide. "The Cosmo Bio agreement is just the first of many we hope to complete in the near future," said Mr. Truscott. "We also look forward to expanding the availability of Canadian-made biological technology that will help advance important drug research."

Dr. Adi Treasurywala, Chief Operating Officer of the Innovations Foundation, said the distribution agreement is an excellent example of what's possible when there is an effective bridge between researchers and industry, the primary mandate of IF. "Good things happen when the right people are brought together," said Mr. Treasurywala.

Researchers value the cell lines because they mimic diseased cells and hence can be used to test the therapeutic effectiveness of drugs, primarily at the discovery stage of research. Key customers include academic institutions and commercial pharmaceutical and biotechnology companies.

CELLutions already has strategic product supply agreements with four Ontario-based academic institutions, and is negotiating similar agreements with several other research institutions across Canada. The company also has plans to expand its offering to include other research tools and reagents. "We have the industry contacts and marketing expertise necessary to sell biological technologies around the world," notes Mr. Truscott.

 
CELLutions Grows Strategic Partnership, Expands Portfolio of Novel Cell Lines
Monday, 29 November 2004
CELLutions Biosystems Inc. is pleased to announce that it has recently acquired the rights to five related novel cell lines, developed by Dr. Yaacov Ben-David and his team at Sunnybrook and Women's College Health Sciences Centre, as part of the recent strategic alliance entered into between the company and this world renowned research institution.

The cell lines come from a mouse erythroleukemia line with distinct growth properties. It grows in the presence of Erythropoietin (Epo) and stem cell factor (SCF), yet undergoes terminal differentiation when stimulated with Epo alone.

"To our knowledge, these are the only cell lines currently available that can undergo terminal erythroid differentiation in response to physiological concentrations of Epo," says Paul Truscott, Vice President, Business Development for CELLutions. "These cell lines have significant utility in a variety of drug discovery and therapeutic development programs, and are currently being used in efforts to discover and identify both Epo-like compounds, as well as Epo antagonists."

The applicability of these efforts is accentuated by the fact that the cells behave almost identically to normal erythroblasts in standard conditions. Other uses of the cells include the identification of downstream effects of Epo, and approaches to discover compounds that behave like, or have similar physiological effects to SCF.

"We are excited to be able to include this novel technology in our product portfolio," says Dr. Adi Treasurywala, President and CEO of CELLutions. "This acquisition is illustrative of the future benefits we expect to achieve through our partnership with Sunnybrook & Women's, ultimately leading us to our goal of becoming the leading supplier of innovative research tools to the research and development market."

About Sunnybrook and Women's College Health Sciences Centre

Sunnybrook and Women's College Health Sciences Centre is transforming health care through the dedication of its more than 8,000 staff members who provide compassionate and innovative patient focused care. An internationally recognized leader in women's health, academic research and education and an affiliation with the University of Toronto distinguishes Sunnybrook & Women's as one of Canada's premier health sciences centres. Sunnybrook & Women's specializes in caring for newborns, adults and the elderly, treating and preventing cancer, heart problems, orthopaedic and arthritic conditions and traumatic injuries. For more information about Sunnybrook, visit: www.sunnybrookandwomens.on.ca.

 
CELLutions Announces Strategic Partnership with Sunnybrook & Women's College Health Sciences Centre
Wednesday, 14 July 2004
CELLutions Biosystems, Inc. is pleased to announce its recent signing of a key strategic alliance with Sunnybrook and Women's College Health Sciences Centre, an internationally recognized leader in women's health, academic research and education.

Through this partnership, CELLutions will acquire the exclusive rights to market and distribute selected novel cell lines and other innovative biological reagents developed by scientists at the Sunnybrook & Women's Research Institute.

CELLutions focuses on the commercialization, marketing, and distribution of innovative cell lines and other research tools for use in basic science, drug discovery, and therapeutic development.

"We are looking forward to developing this new strategic partnership," says Dr. Michael Julius, Vice-President, Research at Sunnybrook & Women's. "Our collaboration with CELLutions will identify promising scientists and research projects that have developed unique cell lines, thus making a valuable impact on the biopharmaceutical industry."

"We intend to use this strategic partnership as a vehicle to build a company with the critical technology mass and the ability to compete on a global scale," says Michael Wasserman, Vice-President, Business Development for CELLutions. "We are working to reach our goal of creating a world-class Canadian organization that will bring cutting-edge technology from Canada's leading academic institutions into widespread use in biopharmaceutical research and development programs globally."

CELLutions will create and implement targeted strategies to maximize the impact of these high potential technologies, and products will be made available to research groups in both the academia and biopharmaceutical industry.

About Sunnybrook and Women's College Health Sciences Centre

Sunnybrook and Women's College Health Sciences Centre is transforming health care through the dedication of its more than 8,000 staff members who provide compassionate and innovative patient focused care. An internationally recognized leader in women's health, academic research and education and an affiliation with the University of Toronto distinguishes Sunnybrook & Women's as one of Canada's premier health sciences centres. Sunnybrook & Women's specializes in caring for newborns, adults and the elderly, treating and preventing cancer, heart problems, orthopaedic and arthritic conditions and traumatic injuries. For more information about Sunnybrook, visit: www.sw.ca.

 
CELLutions Partners with Hospital for Sick Children to Market Innovative Cell Lines & Research Tools
Thursday, 06 May 2004
CELLutions Biosystems, Inc. is pleased to announce its recent partnership agreement with Toronto's Hospital for Sick Children (Sick Kids), one of Canada's foremost research hospitals. Through this strategic alliance, CELLutions will acquire the exclusive rights to market and distribute selected novel cell lines and other biological reagents developed by scientists at Sick Kids.

CELLutions is an innovative biotechnology company focused on the commercialization, marketing, and distribution of cell lines and other research tools for use in basic science, drug discovery, and therapeutic development.

"We are eager to move forward with CELLutions to identify promising scientists and research projects developing unique cell lines," says Dr. Stuart Howe, director, Awards and Business Development at Sick Kids. "In addition, we are very excited about the benefits that this partnership will bring to our institution, through the development and commercialization of research tools that have innate value to the biopharmaceutical industry."

CELLutions will create and implement targeted marketing strategies to maximize the impact of these high potential technologies, and products will be made available to research groups in both academia and the biopharmaceutical industry.

"We intend to use this alliance as a catalyst for further collaborations, with the intent of building a company with the critical technology mass to compete on a global scale," says Michael Wasserman, Vice President, business development for CELLutions. "It is our goal, through the partnership with Sick Kids and other top-tier research centres, to build upon the early success of CELLutions. We are working diligently to create a world-class Canadian organization, bringing cutting-edge technology from Canada's leading academic institutions into widespread use in biopharmaceutical research and development programs around the world."

About The Hospital for Sick Children

The Hospital for Sick Children, affiliated with the University of Toronto, is Canada's most research-intensive hospital, and the largest centre dedicated to improving children's health in the country. Its mission is to provide the best in family-centred, compassionate care, to lead in scientific and clinical advancement, and to prepare the next generation of leaders in child health. For more information about The Hospital for Sick Children, visit: www.sickkids.ca.

 
CELLutions Forms Strategic Alliance with McMaster University
Monday, 22 March 2004
CELLutions Biosystems, Inc. is pleased to announce its recent signing of a key strategic alliance with McMaster University, one of Canada's foremost life sciences research institutions. Through this partnership, CELLutions will acquire the exclusive rights to market and distribute selected novel cell lines and other innovative biological reagents developed by researchers at McMaster.

CELLutions focuses on the commercialization, marketing, and distribution of innovative cell lines and other research tools for use in basic science, drug discovery, and therapeutic development.

"We are very excited about the potential benefits that this strategic partnership will bring to our institution and its researchers," says Mamdouh Shoukri, vice president of research at McMaster University. "We are looking forward to developing this relationship and working together with CELLutions to identify promising scientists and research projects whose work has, or will develop unique cell lines, as well as other research tools that have innate value to the biopharmaceutical industry."

"It is our goal through our partnership with McMaster to build upon the tremendous early success of CELLutions," says Michael Wasserman, vice president, business development for CELLutions. "We are working diligently to create a world-class Canadian organization with the ability to bring cutting-edge technology from Canada's leading academic institutions into widespread use in biopharmaceutical research and development programs around the world. We intend to use this alliance as a catalyst for further collaborations, with the intent of building a company with the critical technology mass to compete on a global scale." CELLutions will create and implement targeted marketing strategies to maximize the impact of these high potential technologies, and products will be made available to research groups in both the academia and biopharmaceutical industry.

About McMaster University

McMaster is a full-service university. Will well-established strengths in health care, engineering, business, social sciences, science and humanities research and education, the University offers both students and professors exciting and unique opportunities for research, education, and collaboration. Through its continued dedication to innovative education and ground-breaking research, the University has earned its reputation as one of the leading post-secondary institutions in Canada. McMaster continues in its commitment to be Canada's most student-centred research university.

 

 

- PHP Notice: Undefined index: color in C:\Inetpub\cellutionsbiosystems.com\templates\clut\index.php on line 29